trastuzumab

Research in Review

Hormone Receptor-Negative Breast Cancers Gain Greatest Economic Benefit from Trastuzumab

12/13/2016

JCP Editors

The cost-effectiveness of adjuvant trastuzumab (Herceptin, Genentech) may vary based on patient age and disease subtype among women with HER2-positive breast cancer, according to study results published in PLoS...

The...

12/13/2016

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

September 18 ⁠–⁠ September 20

September 20 ⁠–⁠ September 22

September 21 ⁠–⁠ September 22

September 30 ⁠–⁠ October 2

October 1 ⁠–⁠ October 2

October 2 ⁠–⁠ October 5

October 5 ⁠–⁠ October 6

October 14 ⁠–⁠ October 16

October 16 ⁠–⁠ October 19

October 19 ⁠–⁠ October 20

See Full Calendar

trastuzumab

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products